Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy

摘要: Chronic inflammation, typical of various diseases including cancer, is a "silent bomb within the body," leading to complications that are only evident in most cases upon their appearance, when disease already deteriorated. inflammation associated with accumulation myeloid-derived suppressor cells (MDSCs), which lead immunosuppression. MDSCs have numerous harmful effects as they support tumor initiation, growth and spreading, turn, perpetuate inflammatory suppressive conditions, thus preventing anticancer responses. As concept immune system combating many types tumors was revived recent years, immunotherapy has dramatically changed view cancer treatment, novel therapies been developed approved by FDA. However, cumulative clinical data point at very limited success rates. It likely developing chronic MDSC-induced immunosuppression interfere responses such treatments hence major obstacles achieving higher response rates immune-based therapies. Moreover, chemotherapies were shown adverse immunoregulatory effects, enhancing or decreasing MDSC levels activity, affecting treatment success. Therefore, therapeutic manipulations during development enhance efficacy immune- chemo-based treatments, switching pro-cancer environments an anticancerous milieu. Based on functional relevance networking tumors, it critical merge monitoring biomarkers into traditional patient's categorization regimens. This will provide new tools for practice, allowing appropriate management patients toward better-personalized medicine.